secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001493152-24-042867
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CFO Mark Andersen resigns; Board member Robert Hoffman appointed Interim CFO
----------------------------------------------------------------------------

- Mark Andersen resigns as CFO effective up to Nov 15, 2024; will transition duties.
- Robert Hoffman, current Board member, appointed Interim CFO effective Oct 30, 2024.
- Hoffman receives $45,833/month cash compensation; steps down from Audit/Compensation Committees.
- Richard Cilento becomes Audit Committee Chairman; Stacy Coen joins Audit; Matthew Link leads Compensation Committee.
- Andersen eligible for nine months base salary severance plus COBRA reimbursement on signing release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224042867/0001493152-24-042867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000149315224042867/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer